A novel proteasome inhibitor acting in mitochondrial dysfunction, ER stress and ROS production

Area of Science:

• Biochemistry
• Molecular Biology
• Pharmacology

Background:

• Cancer therapeutics often induce apoptosis through mechanisms like Bcl-2 family protein regulation, mitochondrial dysfunction, and reactive oxygen species (ROS) production.
• Some drugs induce cancer cell death via proteasome inhibition, leading to endoplasmic reticulum (ER) stress.
• Amblyomin-X is a Kunitz-type inhibitor from the Amblyomma cajennense tick, identified via ESTs sequence analysis.

Purpose of the Study:

• To investigate the apoptotic mechanisms of Amblyomin-X in cancer treatment.
• To determine the selectivity of Amblyomin-X towards tumor cells versus normal cells.

Main Methods:

• Recombinant Amblyomin-X protein was used.
• Apoptosis induction in murine renal adenocarcinoma (RENCA) cells was analyzed.
• Mechanisms including Bcl-2 family protein regulation, mitochondrial function, ROS production, caspase activation, and proteasome inhibition were assessed.
• Effects on normal mouse-fibroblast cells (NHI3T3) were evaluated.

Main Results:

• Amblyomin-X induced apoptosis in RENCA cells.
• The drug caused an imbalance in Bcl-2 family proteins, mitochondrial damage, ROS production, and caspase cascade activation.
• Amblyomin-X also inhibited the proteasome, inducing ER stress.
• No significant effects were observed in normal NHI3T3 cells, indicating tumor-cell selectivity.

Conclusions:

• Amblyomin-X effectively induces apoptosis and ER stress in cancer cells through multiple pathways.
• The observed tumor-cell selectivity suggests Amblyomin-X's potential as a targeted cancer therapeutic.